{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:48:02Z","timestamp":1787676482641,"version":"build-2784847793"},"reference-count":67,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Skeletal muscle tissue (SKM) may be damaged due to mechanical, metabolic, and exertional causes. However, drug-induced myopathy is among the most frequent causes of muscle disease. The clinical picture of drug-induced myopathies may be highly variable. It may present as asymptomatic or mild myalgias, with or without muscle weakness, which are likely underreported. However, it may also appear as chronic myopathy with severe weakness and, rarely, even as massive rhabdomyolysis with acute kidney injury (AKI). Unfortunately, the available biomarkers for SKM injury do not fully meet the needs for satisfactory detection of drug-induced damage, both in clinical and research settings, mainly due to their low sensitivity and specificity. Therefore, the present study proposes a strategy for drug safety monitoring using the available biomarkers of SKM injury. Moreover, we will discuss mechanisms of drug-induced SKM injury, traditional laboratory testing for SKM injury, and novel skeletal myocyte biomarkers under investigation. This can be incredibly useful in both clinical practice and for de-challenge\/re-challenge investigational trials where the risk of drug-induced SKM injury is present.<\/jats:p>","DOI":"10.1515\/cclm-2023-0313","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T23:18:39Z","timestamp":1684192719000},"page":"1688-1699","source":"Crossref","is-referenced-by-count":11,"title":["Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials"],"prefix":"10.1515","volume":"61","author":[{"given":"Patryk","family":"Ostrowski","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Jagiellonian University Medical College , Cracow , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-165X","authenticated-orcid":false,"given":"Micha\u0142","family":"Bonczar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jagiellonian University Medical College , Cracow , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida-Elena","family":"Avram","sequence":"additional","affiliation":[{"name":"Cmed Research Inc. , Morrisville , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry and School of Medicine, University Hospital of Verona , Verona , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Henry","sequence":"additional","affiliation":[{"name":"Cmed Research Inc. , Morrisville , NC , USA"},{"name":"Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"2024012315074098512_j_cclm-2023-0313_ref_001","doi-asserted-by":"crossref","unstructured":"Prendergast, BD, George, CF. Drug-induced rhabdomyolysis\u2013mechanisms and management. Postgrad Med J 1993;69:333\u20136. https:\/\/doi.org\/10.1136\/pgmj.69.811.333.","DOI":"10.1136\/pgmj.69.811.333"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_002","doi-asserted-by":"crossref","unstructured":"Cervellin, G, Comelli, I, Benatti, M, Sanchis-Gomar, F, Bassi, A, Lippi, G. Non-traumatic rhabdomyolysis: background, laboratory features, and acute clinical management. Clin Biochem 2017;50:656\u201362. https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.02.016.","DOI":"10.1016\/j.clinbiochem.2017.02.016"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_003","doi-asserted-by":"crossref","unstructured":"Goldstein, RA. Skeletal muscle injury biomarkers: assay qualification efforts and translation to the clinic. Toxicol Pathol 2017;45:943\u201351. https:\/\/doi.org\/10.1177\/0192623317738927.","DOI":"10.1177\/0192623317738927"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_004","doi-asserted-by":"crossref","unstructured":"Ferrara, R, Pilotto, S, Caccese, M, Grizzi, G, Sperduti, I, Giannarelli, D, et al.. Do immune checkpoint inhibitors need new studies methodology? J\u00a0Thorac Dis 2018;10:S1564\u201380. https:\/\/doi.org\/10.21037\/jtd.2018.01.131.","DOI":"10.21037\/jtd.2018.01.131"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_005","unstructured":"Mastaglia, FL. The changing spectrum of drug-induced myopathies. Acta Myol 2020;39:283\u20138. https:\/\/doi.org\/10.36185\/2532-1900-031."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_006","doi-asserted-by":"crossref","unstructured":"Sieb, JP, Gillessen, T. Iatrogenic and toxic myopathies. Muscle Nerve 2003;27:142\u201356. https:\/\/doi.org\/10.1002\/mus.10244.","DOI":"10.1002\/mus.10244"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_007","unstructured":"Kumar, S, Anne, S, B, HK. Statin induced rhabdomyolysis. J Assoc Physicians India 2021;69:11\u20132."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_008","doi-asserted-by":"crossref","unstructured":"Waclawik, AJ, Lindal, S, Engel, AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993;52:542\u20139. https:\/\/doi.org\/10.1097\/00005072-199309000-00012.","DOI":"10.1097\/00005072-199309000-00012"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_009","doi-asserted-by":"crossref","unstructured":"Mammen, AL. Statin-associated autoimmune myopathy. N Engl J Med 2016;374:664\u20139. https:\/\/doi.org\/10.1056\/NEJMra1515161.","DOI":"10.1056\/NEJMra1515161"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_010","doi-asserted-by":"crossref","unstructured":"Pereira, RMR, Freire de Carvalho, J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78:41\u20134. https:\/\/doi.org\/10.1016\/j.jbspin.2010.02.025.","DOI":"10.1016\/j.jbspin.2010.02.025"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_011","unstructured":"Surmachevska, N, Tiwari, V. Corticosteroid induced myopathy. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_012","doi-asserted-by":"crossref","unstructured":"Dirks-Naylor, AJ, Griffiths, CL. Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 2009;117:1\u20137. https:\/\/doi.org\/10.1016\/j.jsbmb.2009.05.014.","DOI":"10.1016\/j.jsbmb.2009.05.014"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_013","doi-asserted-by":"crossref","unstructured":"Gupta, A, Gupta, Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab 2013;17:913. https:\/\/doi.org\/10.4103\/2230-8210.117215.","DOI":"10.4103\/2230-8210.117215"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_014","unstructured":"Martin, F, Ward, K, Slavin, G, Levi, J, Peters, TJ. Alcoholic skeletal myopathy, a clinical and pathological study. Q J Med 1985;55:233\u201351."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_015","doi-asserted-by":"crossref","unstructured":"Haller, RG, Knochel, JP. Skeletal muscle disease in alcoholism. Med Clin 1984;68:91\u2013103. https:\/\/doi.org\/10.1016\/S0025-7125(16)31243-3.","DOI":"10.1016\/S0025-7125(16)31243-3"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_016","doi-asserted-by":"crossref","unstructured":"Lafair, JS. Alcoholic myopathy. Arch Intern Med 1968;122:417. https:\/\/doi.org\/10.1001\/archinte.1968.00040010417008.","DOI":"10.1001\/archinte.1968.00040010417008"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_017","doi-asserted-by":"crossref","unstructured":"Parks, JM, Reed, G, Knochel, JP. Case report: cocaine-associated rhabdomyolysis. Am J Med Sci 1989;297:334\u20136. https:\/\/doi.org\/10.1097\/00000441-198905000-00013.","DOI":"10.1097\/00000441-198905000-00013"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_018","doi-asserted-by":"crossref","unstructured":"Brody, SL, Wrenn, KD, Wilber, MM, Slovis, CM. Predicting the severity of cocaine-associated rhabdomyolysis. Ann Emerg Med 1990;19:1137\u201343. https:\/\/doi.org\/10.1016\/S0196-0644(05)81518-5.","DOI":"10.1016\/S0196-0644(05)81518-5"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_019","doi-asserted-by":"crossref","unstructured":"Naddaf, E, Paul, P, AbouEzzeddine, OF. Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes. Front Neurol 2021;11:1\u201310. https:\/\/doi.org\/10.3389\/fneur.2020.616075.","DOI":"10.3389\/fneur.2020.616075"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_020","doi-asserted-by":"crossref","unstructured":"Avtna-Zubieta, JA, Johnson, ES, Suarez-Almazor, ME, Russell, AS. Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Rheumatology 1995;34:166\u201370. https:\/\/doi.org\/10.1093\/rheumatology\/34.2.166.","DOI":"10.1093\/rheumatology\/34.2.166"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_021","doi-asserted-by":"crossref","unstructured":"Kuncl, RW, Duncan, G, Watson, D, Alderson, K, Rogawski, MA, Peper, M. Colchicine myopathy and neuropathy. N Engl J Med 1987;316:1562\u20138. https:\/\/doi.org\/10.1056\/NEJM198706183162502.","DOI":"10.1056\/NEJM198706183162502"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_022","doi-asserted-by":"crossref","unstructured":"Carroll, GJ, Will, RK, Peter, JB, Garlepp, MJ, Dawkins, RL. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987;14:995\u20131001.","DOI":"10.1007\/978-94-010-9775-8_31"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_023","doi-asserted-by":"crossref","unstructured":"Halla, JT, Fallahi, S, Koopman, WJ. Penicillamine-induced myositis. Am J Med 1984;77:719\u201322. https:\/\/doi.org\/10.1016\/0002-9343(84)90371-1.","DOI":"10.1016\/0002-9343(84)90371-1"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_024","doi-asserted-by":"crossref","unstructured":"Somani, AK, Swick, AR, Cooper, KD, McCormick, TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008;144:1341\u20139. https:\/\/doi.org\/10.1001\/archderm.144.10.1341.","DOI":"10.1001\/archderm.144.10.1341"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_025","doi-asserted-by":"crossref","unstructured":"Zengin, O, Onder, ME, Alkan, S, Kimyon, G, H\u00fcseynova, N, Demir, ZH, et al.. Three cases of anti-TNF induced myositis and literature review. Rev Bras Reumatol 2017;57:590\u20135. https:\/\/doi.org\/10.1016\/j.rbre.2016.05.003.","DOI":"10.1016\/j.rbre.2016.05.003"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_026","doi-asserted-by":"crossref","unstructured":"Rawson, ES, Clarkson, PM, Tarnopolsky, MA. Perspectives on exertional rhabdomyolysis. Sports Med 2017;47:33\u201349. https:\/\/doi.org\/10.1007\/s40279-017-0689-z.","DOI":"10.1007\/s40279-017-0689-z"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_027","doi-asserted-by":"crossref","unstructured":"Liewluck, T, Kao, JC, Mauermann, ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 2018;41:208\u201311. https:\/\/doi.org\/10.1097\/CJI.0000000000000196.","DOI":"10.1097\/CJI.0000000000000196"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_028","doi-asserted-by":"crossref","unstructured":"Albarr\u00e1n-Artahona, V, Laguna, J-C, Gorr\u00eda, T, Torres-Jim\u00e9nez, J, Pascal, M, Mezquita, L. Immune-related uncommon adverse events in patients with cancer treated with immunotherapy. Diagnostics 2022;12:2091. https:\/\/doi.org\/10.3390\/diagnostics12092091.","DOI":"10.3390\/diagnostics12092091"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_029","doi-asserted-by":"crossref","unstructured":"Shelly, S, Triplett, JD, Pinto, MV, Milone, M, Diehn, FE, Zekeridou, A, et al.. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2020;2:1\u201316. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181.","DOI":"10.1093\/braincomms\/fcaa181"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_030","doi-asserted-by":"crossref","unstructured":"Tomoaia, R, Beyer, R\u0218, Pop, D, Minciun\u0103, IA, D\u0103d\u00e2rlat-Pop, A. Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade. Eur J Cancer 2020;132:224\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.003.","DOI":"10.1016\/j.ejca.2020.03.003"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_031","doi-asserted-by":"crossref","unstructured":"Ruggeri, EM, Cecere, FL, Moscetti, L, Doni, L, Padalino, D, Di Costanzo, F. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases. Ann Oncol 2010;21:1926\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdq395.","DOI":"10.1093\/annonc\/mdq395"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_032","doi-asserted-by":"crossref","unstructured":"Hugo Javier, Madariaga Charaja, Valery, Ascu\u00f1a. Abstracts, 21st PANLAR meeting. J Clin Rheumatol 2019;25:S1-96. https:\/\/doi.org\/10.1097\/RHU.0000000000001070.","DOI":"10.1097\/RHU.0000000000001070"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_033","doi-asserted-by":"crossref","unstructured":"Liman, AD, Passero, VA, Liman, AK, Shields, J. A rare case of sunitinib-induced rhabdomyolysis in renal cell carcinoma. Case Rep Oncol Med 2018;2018:1\u20134. https:\/\/doi.org\/10.1155\/2018\/3808523.","DOI":"10.1155\/2018\/3808523"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_034","unstructured":"Huot, JR, Pin, F, Bonetto, A. Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity. Am J Cancer Res 2021;11:2990\u20133001."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_035","doi-asserted-by":"crossref","unstructured":"Dewys, WD, Begg, C, Lavin, PT, Band, PR, Bennett, JM, Bertino, JR, et al.. Prognostic effect of weight loss prior tochemotherapy in cancer patients. Am J Med 1980;69:491\u20137. https:\/\/doi.org\/10.1016\/S0149-2918(05)80001-3.","DOI":"10.1016\/S0149-2918(05)80001-3"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_036","doi-asserted-by":"crossref","unstructured":"von Haehling, S, Anker, SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle 2014;5:261\u20133. https:\/\/doi.org\/10.1007\/s13539-014-0164-8.","DOI":"10.1007\/s13539-014-0164-8"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_037","unstructured":"Melstrom, LG, Melstrom, KA, Ding, XZ, Adrian, TE. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 2007;22:805\u201314. https:\/\/doi.org\/10.14670\/HH-22.805."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_038","doi-asserted-by":"crossref","unstructured":"Lecker, SH, Solomon, V, Mitch, WE, Goldberg, AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999;129:227S\u201337S. https:\/\/doi.org\/10.1093\/jn\/129.1.227S.","DOI":"10.1093\/jn\/129.1.227S"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_039","doi-asserted-by":"crossref","unstructured":"Spielmann, L, Messer, L, Moreau, P, Etienne, E, Meyer, C, Sibilia, J, et al.. Gemcitabine-induced myopathy. Semin Arthritis Rheum 2014;43:784\u201391. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.11.009.","DOI":"10.1016\/j.semarthrit.2013.11.009"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_040","doi-asserted-by":"crossref","unstructured":"Burris, HA, Hurtig, J. Radiation recall with anticancer agents. Oncologist 2010;15:1227\u201337. https:\/\/doi.org\/10.1634\/theoncologist.2009-0090.","DOI":"10.1634\/theoncologist.2009-0090"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_041","unstructured":"Ardavanis, AS, Ioannidis, GN, Rigatos, GA. Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res 2005;25:523\u20135."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_042","doi-asserted-by":"crossref","unstructured":"Deangelis, LM, Gnecco, C, Taylor, L, Warrell, RP. Evolution of neuropathy and myopathy during intensive vincristine\/corticosteroid chemotherapy for non-Hodgkin\u2019s lymphoma. Cancer 1991;67:2241\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19910501)67:9<2241::AID-CNCR2820670905>3.0.CO;2-A.","DOI":"10.1002\/1097-0142(19910501)67:9<2241::AID-CNCR2820670905>3.0.CO;2-A"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_043","doi-asserted-by":"crossref","unstructured":"Le Quintrec, JS, Le Quintrec, JL. Drug-induced myopathies. Baillieres Clin Rheumatol 1991;5:21\u201338. https:\/\/doi.org\/10.1016\/S0950-3579(05)80294-8.","DOI":"10.1016\/S0950-3579(05)80294-8"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_044","doi-asserted-by":"crossref","unstructured":"McLeish, MJ, Kenyon, GL. Relating structure to mechanism in creatine kinase. Crit Rev Biochem Mol Biol 2005;40:1\u201320. https:\/\/doi.org\/10.1080\/10409230590918577.","DOI":"10.1080\/10409230590918577"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_045","doi-asserted-by":"crossref","unstructured":"Lippi, G, Schena, F, Ceriotti, F. Diagnostic biomarkers of muscle injury and exertional rhabdomyolysis. Clin Chem Lab Med 2018;57:175\u201382. https:\/\/doi.org\/10.1515\/cclm-2018-0656.","DOI":"10.1515\/cclm-2018-0656"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_046","doi-asserted-by":"crossref","unstructured":"Paidoussis, D. Severe rhabdomyolysis associated with a popular high-intensity at-home exercise program. J Med Cases 2012;4:12\u20134. https:\/\/doi.org\/10.4021\/jmc875w.","DOI":"10.4021\/jmc875w"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_047","doi-asserted-by":"crossref","unstructured":"Pettersson, J, Hindorf, U, Persson, P, Bengtsson, T, Malmqvist, U, Werkstr\u00f6m, V, et al.. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol 2008;65:253\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03001.x.","DOI":"10.1111\/j.1365-2125.2007.03001.x"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_048","doi-asserted-by":"crossref","unstructured":"Tietze, DC, Borchers, J. Exertional rhabdomyolysis in the athlete. Sport Health: A Multidiscip Approach 2014;6:336\u20139. https:\/\/doi.org\/10.1177\/1941738114523544.","DOI":"10.1177\/1941738114523544"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_049","unstructured":"Aujla, RS, Patel, R. Creatine phosphokinase. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"2024012315074098512_j_cclm-2023-0313_ref_050","doi-asserted-by":"crossref","unstructured":"Brewster, LM, Mairuhu, G, Sturk, A, van Montfrans, GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 2007;154:655\u201361. https:\/\/doi.org\/10.1016\/j.ahj.2007.06.008.","DOI":"10.1016\/j.ahj.2007.06.008"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_051","doi-asserted-by":"crossref","unstructured":"Lippi, G, Banfi, G. Distribution of creatine kinase in sedentary and physically active individuals. Am Heart J 2008;155:e51. https:\/\/doi.org\/10.1016\/j.ahj.2008.02.017.","DOI":"10.1016\/j.ahj.2008.02.017"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_052","doi-asserted-by":"crossref","unstructured":"Gros, G, Wittenberg, BA, Jue, T. Myoglobin\u2019s old and new clothes: from molecular structure to function in living cells. J Exp Biol 2010;213:2713\u201325. https:\/\/doi.org\/10.1242\/jeb.043075.","DOI":"10.1242\/jeb.043075"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_053","doi-asserted-by":"crossref","unstructured":"Gabow, PA, Kaehny, WD, Kelleher, SP. The spectrum of rhabdomyolysis. Medicine 1982;61:141\u201352. https:\/\/doi.org\/10.1097\/00005792-198205000-00002.","DOI":"10.1097\/00005792-198205000-00002"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_054","doi-asserted-by":"crossref","unstructured":"Pal, S, Chaki, B, Chattopadhyay, S, Bandyopadhyay, A. High-intensity exercise induced oxidative stress and skeletal muscle damage in postpubertal boys and girls: a comparative study. J Strength Condit Res 2018;32:1045\u201352. https:\/\/doi.org\/10.1519\/JSC.0000000000002167.","DOI":"10.1519\/JSC.0000000000002167"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_055","doi-asserted-by":"crossref","unstructured":"Apple, FS. Serum and muscle alanine aminotransferase activities in marathon runners. JAMA, J Am Med Assoc 1984;252:626. https:\/\/doi.org\/10.1001\/jama.1984.03350050018012.","DOI":"10.1001\/jama.1984.03350050018012"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_056","doi-asserted-by":"crossref","unstructured":"Lim, AK. Abnormal liver function tests associated with severe rhabdomyolysis. World J Gastroenterol 2020;26:1020\u20138. https:\/\/doi.org\/10.3748\/wjg.v26.i10.1020.","DOI":"10.3748\/wjg.v26.i10.1020"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_057","doi-asserted-by":"crossref","unstructured":"Lim, AKH, Arumugananthan, C, Lau, H, Yim, C, Jellie, LJ, Wong, EWW, et al.. A cross-sectional study of the relationship between serum creatine kinase and liver biochemistry in patients with rhabdomyolysis. J Clin Med 2019;9:81. https:\/\/doi.org\/10.3390\/jcm9010081.","DOI":"10.3390\/jcm9010081"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_058","doi-asserted-by":"crossref","unstructured":"Castro, C, Gourley, M. Diagnosis and treatment of inflammatory myopathy: issues and management. Ther Adv Musculoskelet Dis 2012;4:111\u201320. https:\/\/doi.org\/10.1177\/1759720X11425092.","DOI":"10.1177\/1759720X11425092"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_059","doi-asserted-by":"crossref","unstructured":"Delanghe, JR, Speeckaert, MM, De Buyzere, ML. Is creatine kinase an ideal biomarker in rhabdomyolysis? Reply to Lippi et\u00a0al.: diagnostic biomarkers of muscle injury and exertional rhabdomyolysis (https:\/\/doi.org\/10.1515\/cclm-2018-0656). Clin Chem Lab Med 2019;57:e75\u20136. https:\/\/doi.org\/10.1515\/cclm-2018-1320.","DOI":"10.1515\/cclm-2018-1320"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_060","doi-asserted-by":"crossref","unstructured":"Bicker, A, Nauth, T, Gerst, D, Aboouf, M, Fandrey, J, Kristiansen, G, et al.. The role of myoglobin in epithelial cancers: insights from transcriptomics. Int J Mol Med 2019;45:385\u2013400. https:\/\/doi.org\/10.3892\/ijmm.2019.4433.","DOI":"10.3892\/ijmm.2019.4433"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_061","doi-asserted-by":"crossref","unstructured":"Silverman, LM, Dermer, GB, Zweig, MH, Van Steirteghem, AC, T\u00f6k\u00e9s, ZA. Creatine kinase BB: a new tumor-associated marker. Clin Chem 1979;25:1432\u20135. https:\/\/doi.org\/10.1093\/clinchem\/25.8.1432.","DOI":"10.1093\/clinchem\/25.8.1432"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_062","doi-asserted-by":"crossref","unstructured":"Sietsema, KE, Meng, F, Yates, NA, Hendrickson, RC, Liaw, A, Song, Q, et al.. Potential biomarkers of muscle injury after eccentric exercise. Biomarkers 2010;15:249\u201358. https:\/\/doi.org\/10.3109\/13547500903502802.","DOI":"10.3109\/13547500903502802"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_063","doi-asserted-by":"crossref","unstructured":"Harju, AK, Bootorabi, F, Kuuslahti, M, Supuran, CT, Parkkila, S. Carbonic anhydrase III: a neglected isozyme is stepping into the limelight. J\u00a0Enzym Inhib Med Chem 2013;28:231\u20139. https:\/\/doi.org\/10.3109\/14756366.2012.700640.","DOI":"10.3109\/14756366.2012.700640"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_064","doi-asserted-by":"crossref","unstructured":"Beuerle, JR, Azzazy, HM, Styba, G, Duh, SH, Christenson, RH. Characteristics of myoglobin, carbonic anhydrase III and the myoglobin\/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients. Clin Chim Acta 2000;294:115\u201328. https:\/\/doi.org\/10.1016\/s0009-8981(99)00261-2.","DOI":"10.1016\/S0009-8981(99)00261-2"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_065","doi-asserted-by":"crossref","unstructured":"Vlasakova, K, Lane, P, Michna, L, Muniappa, N, Sistare, FD, Glaab, WE. Response of novel skeletal muscle biomarkers in dogs to drug-induced skeletal muscle injury or sustained endurance exercise. Toxicol Sci 2017;156:kfw262. https:\/\/doi.org\/10.1093\/toxsci\/kfw262.","DOI":"10.1093\/toxsci\/kfw262"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_066","doi-asserted-by":"crossref","unstructured":"Burch, PM, Greg Hall, D, Walker, EG, Bracken, W, Giovanelli, R, Goldstein, R, et al.. Evaluation of the relative performance of drug-induced skeletal muscle injury biomarkers in rats. Toxicol Sci 2016;150:247\u201356. https:\/\/doi.org\/10.1093\/toxsci\/kfv328.","DOI":"10.1093\/toxsci\/kfv328"},{"key":"2024012315074098512_j_cclm-2023-0313_ref_067","doi-asserted-by":"crossref","unstructured":"Giannitsis, E, Mueller, C, Katus, HA. Skeletal myopathies as a non-cardiac cause of elevations of cardiac troponin concentrations. Diagnosis 2019;6:189\u2013201. https:\/\/doi.org\/10.1515\/dx-2019-0045.","DOI":"10.1515\/dx-2019-0045"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0313\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0313\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T15:11:50Z","timestamp":1706022710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0313\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,4,4]]},"published-print":{"date-parts":[[2023,9,26]]}},"alternative-id":["10.1515\/cclm-2023-0313"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2023-0313","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}